| Abstract: |
CAR T-cell therapy is a recent therapeutic advancement that has transformed the management of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). To date, there are 2 FDA-approved CAR-T products for R/R B-ALL: tisagenlecleucel in patients aged,26 years and brexucabtagene autoleucel in those aged $18 years. This review summarizes the pivotal clinical trials that led to FDA approval of these 2 products and highlight emerging data addressing key questions pertinent to CAR-T utilization in the rapidly evolving landscape of R/R ALL management. These include optimal sequencing of CAR-T among other novel immunotherapeutic agents, the role of consolidation and maintenance following CAR-T, novel CAR-T constructs currently under clinical development, and strategies to optimize use of commercially available CAR-T products to improve patient outcomes. © 2024 Harborside Press. All rights reserved. |
| Keywords: |
adult; child; treatment outcome; genetics; review; clinical trials as topic; neoplasm recurrence, local; food and drug administration; acute lymphoblastic leukemia; immunology; drug combination; receptors, antigen, t-cell; tumor recurrence; chimeric antigen receptor; drug therapy; therapy; adoptive immunotherapy; immunotherapy, adoptive; lymphocyte antigen receptor; b cell leukemia; clinical trial (topic); procedures; humans; human; pharmacoeconomics; b cell acute lymphoblastic leukemia; tisagenlecleucel t; chimeric antigen receptor t-cell immunotherapy; chimeric antigen receptor t-cell; receptors, chimeric antigen; precursor b-cell lymphoblastic leukemia-lymphoma; brexucabtagene autoleucel
|
